NR in Chemo-induced Peripheral Neuropathy

Sponsor / Institution: National Cancer Institute (NCI), ChromaDex Inc., University of Iowa

Purpose

To determine whether NR (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving paclitaxel for treatment of stage IV breast cancer or platinum-resistant recurrent ovarian cancer

Study Design

Single group assignment

Dose

300mg NR daily (150mg 2x/day) for one week with dose escalation to 1000mg (500mg 2x/day) for remaining 11 weeks

Length of Intervention

12 weeks

Intrinsic Capacity

Sensory

Status

Recruiting

Condition or Disease 

Chemotherapy-induced Peripheral Neuropathy
Breast Cancer Metastatic
Platinum-resistant Recurrent Ovarian Cancer

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical Studies, Sensory, RecruitingANAD Staff